secwatch.observer — SEC 8-K summary
======================================

Issuer:     TherapeuticsMD, Inc. (TXMD)
CIK:        0000025743
Form:       8-K
Filed at:   2022-05-31T23:59:59+00:00
Accession:  0001564590-22-021755
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TherapeuticsMD to be acquired by EW Healthcare Partners for $10.00/share in all-cash deal
--------------------------------------------------------------------------------

- Offer price of $10.00 per share represents 367.3% premium over May 27 closing price.
- Total enterprise value approx. $177 million; tender offer to commence by June 6, 2022.
- Board unanimously approved; no stockholder vote required under Nevada law.
- Financing: $93M equity commitment from EW; Sixth Street debt amended with interest pause and maturity extended to July 13, 2022.
- If merger fails to close by July 13, 2022, events of default under financing agreement could impact going concern.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/25743/000156459022021755/0001564590-22-021755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/25743/000156459022021755/txmd-8k_20220527.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-021755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer